BioMedPartners
Venture capitalBasel · Seed–Late Stage · 28 people tracked
Investment thesis
BiomedVC backs the next generation of European life science entrepreneurs, helping translate scientific innovation from academic labs into venture-backed biotechs developing therapeutics for high-unmet medical needs. The firm makes initial Seed and Series A investments, leads and co-leads rounds, and reserves capital for follow-on financings. It focuses on continental Europe with an emphasis on the DACH region, particularly Switzerland and Germany. BiomedVC continues the legacy of predecessor BioMedPartners, one of the earliest life-science-focused early-stage VCs in continental Europe. The firm is raising its new fund, BiomedInvest IV, and has already built a significant portfolio of biotech start-ups in Switzerland and Germany.
Source: firm website, verified Aug 7, 2026.
Team · 28 people
from the firm's website & public directories
What they invest in
from 5 of 21 portfolio companiesBiotech ×5Medical Devices ×4Healthtech ×3Hardware ×1
HQs:France×1
Investments · 21 tracked
founders shown can be your intro pathBiotech targeting hard-to-drug intracellular protein-protein interactions with crosslinked helix dimers.
Developing a targeted intracellular drug delivery platform with an oncology pipeline.
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Immunotherapies for T cell-mediated autoimmune conditions via modulation of coronin 1; spin-off from the University of Basel.
Develops novel therapeutics through protein, DNA, and RNA engineering.
Developing antibodies targeting TNF and TNF superfamily members for improved safety and bispecific therapies.
Clinical-stage CAR-T programs with a proprietary non-viral in vivo CAR-T platform.
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Biotech
Topas Therapeutics develops a nanoparticle platform technology to establish immune tolerance in autoimmune and immune-mediated diseases.
BiotechMedical Devices
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation.
BiotechHardwareHealthtechMedical DevicesFrance, FR
Ahmed Elmouelhi(President & CEO)Esther Gerteis(Senior VP Medical & Regulatory Affairs)Michael Litzenburger(VP R&D)
Germany-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, acquired by Gilead Sciences for $3.15 billion upfront plus up to $1.85 billion in contingent payments.
Exits · 1
IPOs and acquisitions across the tracked portfolioTubulis GmbHacq. by Gilead Sciences
Frequently asked questions
- What stage does BioMedPartners invest at?
- BioMedPartners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is BioMedPartners's typical check size?
- BioMedPartners typically writes checks of $648K – $6.5M.
- What sectors does BioMedPartners focus on?
- BioMedPartners focuses on Biotech, Healthtech, Medical Devices.
- Where is BioMedPartners located?
- BioMedPartners is headquartered in Basel, CH.
- Does BioMedPartners lead rounds?
- Yes, BioMedPartners leads investment rounds.
Images
Similar investors
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.